Publication: Türkiye ilaç sektöründe araştırma-geliştirme kapasitesinin gelişimi ve rekabet gücü üzerindeki etkileri
Abstract
Türkiye ilaç sektöründe araştırma-geliştirme kapasitesinin gelişimi ve rekabet gücü üzerindeki etkileri İlaç endüstrisi, küresel ölçekte etkili olan stratejik bir sektörü oluşturmaktadır. Ekonomik gelişimini sürdüren bu sektör, sağlık politikalarının şekillenmesinde belirleyici bir rol oynamaktadır. Çok boyutlu bir yapıya sahip olan sektörde hem özel girişimler hem de kamu destekli organizasyonlar faaliyet göstermektedir. Bununla birlikte ilaç endüstrisinin en önemli unsurlarından biri Ar-Ge projeleridir. Ar-Ge faaliyetleri, bilimsel standartlara uygun olarak yürütülmektedir. Ve inovasyon çalışmaları, biyoteknolojik gelişmeler, kimyasal altyapılar ve tıbbi uygulamalar bu faaliyetin temelini oluşturmaktadır. Türkiye’de ilaç endüstrisindeki Ar-Ge çalışmaları gelişimini sürdürmektedir. Bu araştırmada, Türkiye’de yürütülen ilaç Ar-Ge faaliyetlerinin pazardaki konum ve rekabet gücü üzerine olan etkisi incelenmiştir. Çalışmada nitel araştırma yöntemlerinden olan görüşme tekniği kullanılarak Türkiye’de ilaç sektöründe faaliyetlerini sürdüren firmaların Ar-Ge çalışmaları çeşitli açılardan incelenmiştir. Firma yetkilileri ile gerçekleştirilen görüşmeler sonucunda elde edilen veriler, içerik analizi ile analiz edilmiştir. Bulgular neticesinde ilaç sektöründeki firmaların Ar-Ge faaliyetlerde bulunması, yenilikçi ürün geliştirme kapasitesini artırarak pazardaki konumunu ve rekabet gücünü olumlu yönden etkileyeceği ve firmaların bunun bilincinde olarak faaliyette bulundukları görülmüştür. Bununla birlikte Türkiye ilaç sektöründe Ar-Ge çalışmalarının büyük ölçüde jenerik ilaç üretimi merkezinde yapıldığı ortaya konmuştur. Sektörde rekabet, çoğunlukla pazara ilk girerek “ first to market” olma hedefi üzerinden şekillenmektedir. Çalışma ayrıca, Türkiye ilaç sektörünün Ar-Ge ve diğer ekosistem bileşenleri açısından uluslararası düzeyde bir potansiyele sahip olduğunu, ancak finansal kaynak yetersizlikleri nedeniyle güçlü bir Ar-Ge kültürünün oluşamadığını ve bu nedenle orijinal ilaç geliştirme çalışmalarının gerçekleştirilemediğini göstermektedir.
Analysis of the development and size of R&D activities in the Turkish pharmaceutical sector in terms of capacity and competition The pharmaceutical industry constitutes a strategic sector with a global impact. This sector, which continues its economic development, plays a decisive role in shaping health policies. The multifaceted sector encompasses both private initiatives and publicly funded organizations. R&D projects are a key component of the pharmaceutical industry. R&D activities are conducted in accordance with scientific standards. Innovation, biotechnological developments, chemical infrastructures, and medical applications form the basis of this activity. R&D studies in the pharmaceutical industry in Turkey continue to develop. In this research, the impact of pharmaceutical R&D activities carried out in Türkiye on market position and competitiveness was examined. In this study, the R&D activities of companies operating in the pharmaceutical sector in Turkey were examined from various perspectives using the interview technique, which is one of the qualitative research methods. The data obtained as a result of interviews with company officials were analyzed using content analysis. As a result of the findings, it has been observed that the R&D activities of the companies in the pharmaceutical sector will positively affect their market position and competitiveness by increasing their innovative product development capacity, and the companies are operating with this awareness. However, it has been revealed that R&D studies in the Turkish pharmaceutical industry are largely carried out in generic drug production centers. Competition in the sector is often shaped by the goal of being “first to market” by entering the market first. The study also shows that the Turkish pharmaceutical industry has international potential in terms of R&D and other ecosystem components, but due to lack of financial resources, a strong R&D culture cannot be established and therefore original drug development studies cannot be carried out.
Analysis of the development and size of R&D activities in the Turkish pharmaceutical sector in terms of capacity and competition The pharmaceutical industry constitutes a strategic sector with a global impact. This sector, which continues its economic development, plays a decisive role in shaping health policies. The multifaceted sector encompasses both private initiatives and publicly funded organizations. R&D projects are a key component of the pharmaceutical industry. R&D activities are conducted in accordance with scientific standards. Innovation, biotechnological developments, chemical infrastructures, and medical applications form the basis of this activity. R&D studies in the pharmaceutical industry in Turkey continue to develop. In this research, the impact of pharmaceutical R&D activities carried out in Türkiye on market position and competitiveness was examined. In this study, the R&D activities of companies operating in the pharmaceutical sector in Turkey were examined from various perspectives using the interview technique, which is one of the qualitative research methods. The data obtained as a result of interviews with company officials were analyzed using content analysis. As a result of the findings, it has been observed that the R&D activities of the companies in the pharmaceutical sector will positively affect their market position and competitiveness by increasing their innovative product development capacity, and the companies are operating with this awareness. However, it has been revealed that R&D studies in the Turkish pharmaceutical industry are largely carried out in generic drug production centers. Competition in the sector is often shaped by the goal of being “first to market” by entering the market first. The study also shows that the Turkish pharmaceutical industry has international potential in terms of R&D and other ecosystem components, but due to lack of financial resources, a strong R&D culture cannot be established and therefore original drug development studies cannot be carried out.